Chemocentryx Inc (NASDAQ:CCXI) had a decrease of 17.4% in short interest. CCXI’s SI was 1.11M shares in March as released by FINRA. Its down 17.4% from 1.34 million shares previously. With 407,200 avg volume, 3 days are for Chemocentryx Inc (NASDAQ:CCXI)’s short sellers to cover CCXI’s short positions. The SI to Chemocentryx Inc’s float is 4.64%. The stock increased 4.36% or $0.58 during the last trading session, reaching $13.89. About 408,035 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 12.22% since March 31, 2018 and is uptrending. It has outperformed by 7.85% the S&P500. Some Historical CCXI News: 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 31/03/2018 – ChemoCentryx Conference Set By H.C. Wainwright for Apr. 8-10; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 20/04/2018 – DJ Chemocentryx Inc, Inst Holders, 1Q 2018 (CCXI); 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 09/05/2018 – CHEMOCENTRYX INC – QTRLY DILUTED NET LOSS PER COMMON SHARE $0.19; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA
In a a report revealed to clients and investors on Sunday morning, BidaskScore stated it was upgrading AAON (NASDAQ:AAON) stock to a Buy.
Since October 16, 2018, it had 0 buys, and 8 insider sales for $87.64 million activity. The insider Cappel Markus J. sold $332,779. On Thursday, January 10 Schall Thomas J. sold $447,092 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) or 36,762 shares. Another trade for 7.34M shares valued at $85.85 million was made by GLAXOSMITHKLINE PLC on Tuesday, October 16. $457,747 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) shares were sold by KANAYA SUSAN M.
Among 5 analysts covering ChemoCentryx (NASDAQ:CCXI), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ChemoCentryx had 5 analyst reports since November 12, 2018 according to SRatingsIntel. Leerink Swann initiated the stock with “Buy” rating in Thursday, February 14 report. The firm has “Buy” rating given on Wednesday, March 27 by FBR Capital. H.C. Wainwright maintained ChemoCentryx, Inc. (NASDAQ:CCXI) rating on Tuesday, March 12. H.C. Wainwright has “Buy” rating and $23 target. Canaccord Genuity maintained it with “Buy” rating and $20 target in Monday, November 12 report.
Investors sentiment decreased to 0.93 in Q4 2018. Its down 0.05, from 0.98 in 2018Q3. It worsened, as 7 investors sold ChemoCentryx, Inc. shares while 38 reduced holdings. 18 funds opened positions while 24 raised stakes. 27.13 million shares or 1.23% more from 26.80 million shares in 2018Q3 were reported. State Street Corp holds 487,355 shares or 0% of its portfolio. Citigroup Incorporated holds 0% or 4,073 shares. Aqr Capital Mngmt Limited Liability Corporation holds 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 22,364 shares. Blackrock has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 2.73M shares. Alps Inc owns 156,559 shares or 0.01% of their US portfolio. Barclays Public Limited holds 0% or 5,866 shares. The Massachusetts-based Fernwood Invest Management Ltd Liability Co has invested 0.07% in ChemoCentryx, Inc. (NASDAQ:CCXI). Citadel Advsrs Ltd Liability Co invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Trexquant Invest Limited Partnership holds 33,717 shares. Daiwa Securities Grp has invested 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Federated Pa has invested 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Sio Mgmt Limited Liability Corp owns 169,257 shares. 103,341 were reported by Cadence Capital Mngmt Ltd. Sectoral Asset Management holds 17,811 shares or 0.03% of its portfolio. 84,345 were reported by Deutsche Bank Ag.
More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Globenewswire.com which released: “ChemoCentryx Appoints Rita Jain, M.D. to Board of Directors – GlobeNewswire” on March 28, 2019, also Nasdaq.com with their article: “ChemoCentryx (CCXI) Reports Q4 Loss, Lags Revenue Estimates – Nasdaq” published on March 11, 2019, Nasdaq.com published: “ChemoCentryx (CCXI) Looks Good: Stock Adds 5.5% in Session – Nasdaq” on March 19, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Nasdaq.com and their article: “After-Hours Earnings Report for March 11, 2019 : ADT, COUP, SFIX, DRNA, AVD, PETQ, CCXI, LXFR, MG, OXFD, FRTA, KALA – Nasdaq” published on March 11, 2019 as well as Benzinga.com‘s news article titled: “60 Stocks Moving In Wednesday’s Mid-Day Session – Benzinga” with publication date: March 27, 2019.
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $730.19 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It currently has negative earnings. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.
AAON, Inc., together with its subsidiaries, engages in engineering, manufacturing, marketing, and selling air conditioning and heating equipment in the United States and Canada. The company has market cap of $2.40 billion. It offers rooftop units, chillers, packaged outdoor mechanical rooms, air handling units, makeup air units, energy recovery units, condensing units, geothermal/water-source heat pumps, self-contained units, and coils. It has a 57.01 P/E ratio. The firm markets and sells its products to retail, manufacturing, educational, lodging, supermarket, medical, and other commercial industries.
More notable recent AAON, Inc. (NASDAQ:AAON) news were published by: Nasdaq.com which released: “Why AAON, Inc. (AAON) Stock Might be a Great Pick – Nasdaq” on March 22, 2019, also Globenewswire.com with their article: “AAON Authorizes $20 Million for Stock Buyback Program – GlobeNewswire” published on March 05, 2019, Nasdaq.com published: “Aaon (AAON) is a Great Momentum Stock: Should You Buy? – Nasdaq” on March 12, 2019. More interesting news about AAON, Inc. (NASDAQ:AAON) were released by: Nasdaq.com and their article: “Top-Ranked Stocks to Fill in the Sweet 16 Bracket – Nasdaq” published on March 28, 2019 as well as Nasdaq.com‘s news article titled: “The Zacks Analyst Blog Highlights: Booz Allen Hamilton, iRobot, CNOOC and Great Lakes Dredge & Dock – Nasdaq” with publication date: March 29, 2019.
Since November 8, 2018, it had 0 buys, and 2 sales for $470,419 activity. On Thursday, November 8 the insider Short Jack E sold $399,670. Fields Gary D sold $70,749 worth of stock.
The stock increased 0.79% or $0.36 during the last trading session, reaching $46.18. About 142,107 shares traded or 11.69% up from the average. AAON, Inc. (NASDAQ:AAON) has risen 17.86% since March 31, 2018 and is uptrending. It has outperformed by 13.49% the S&P500. Some Historical AAON News: 16/03/2018 – AAON REPORTS OFFICER RESIGNATION; 06/03/2018 Aaon Closes Above 50-Day Moving Average: Technicals; 23/03/2018 – AAON Announces Price Increase of Up to 5% on HVAC Equipment, Effective June 15; 03/05/2018 – AAON Inc. 1Q EPS 8c; 18/05/2018 – AAON BOOSTS QTR DIV TO 16C/SHR FROM 13C, EST. 15C; 23/04/2018 – DJ AAON Inc, Inst Holders, 1Q 2018 (AAON); 18/05/2018 – Aaon Raises Semi-Annual Dividend to 16c Vs. 13c; 16/03/2018 – AAON Announces Officer Resignation; 03/05/2018 – AAON Federal Corporate Tax Rate Cut to 21% From 35% After Bonuses Paid to Employees; 23/03/2018 – AAON Announces Price Increase
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.